JACKSON CENTER, PA / ACCESSWIRE / April 8, 2020 / Premier Biomedical, Inc. (OTCPINK:BIEI), Halberd Corporation (HALB) and Gold River Productions Inc. (GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier's Anti-Addiction Patch™.
The Joint Venture on Covid-19 treatment starts with Dr. Mitchell Felder's patented extracorporeal therapy (US Patent 9,216,386 and US Patent 8,758,287) for the safe removal of targeted antigens from the blood and targeted organs. Dr. Felder explained, "The extracorporeal treatment is based on the process of removing the underlying basis of the disease. In the case of Covid-19, it entails removal of specific compounds which allow the virus to replicate. We believe this technology is superior to known treatments in that it may potentially eliminate mutations of the virus."
Dr. Richard Goulding, Gold River's Chief Medical Officer stated, "Premier's multi-faceted extracorporeal technology can be used to remove the disease-causing antigens and to prevent the "cytokine storm" associated with the disease in severely ill patients."
Dr. Felder continued, "With our partners, including a leading university partner, we are now positioned to develop potential cures and mitigation for Covid-19 as well as to alleviate the global drug epidemic for our country and the world. The joint venture includes financial commitments for funding, which if obtained, along with the continued research with our university partner is likely to develop the technology disclosed in our provisional patent application entitled ‘Method for Treating and Curing COVID-19 Infection'. We seek to further develop and establish proof of concept with regard to these promising tools in this worldwide battle. This positions us to facilitate defenses against the growing COVID-19 menace as well as against other viral attacks."
See YouTube video, https://youtu.be/BGdZqHH6oew , concerning Dr. Felder's discussion of the scientific basis underlying Premier's extracorporeal treatment process for fighting cancer and other diseases.
"With COVID-19 spreading at an alarming rate, we have accelerated our efforts to develop effective tools to combat not just COVID-19 but other viruses as they occur. Therefore, we are working on a composite and generalized series of defenses and remedial measures to combat and to otherwise cope with viruses, even as they mutate, adapt or otherwise change," commented Dr. Goulding.
"Perhaps more importantly," continued Dr. Goulding "this extracorporeal treatment could complement and work in tandem with an effective vaccine. In other words, a vaccine would treat the disease, but often of equal importance is treating the harmful consequences of the disease, including the removal of the deleterious cytokines which ultimately cause the damage to the human body and even death."
James Christopher Ledoux, CEO of Halberd, stated, "This is a very exciting alliance! The team we are now assembling is poised to make significant contributions to overcoming the Covid-19 pandemic as well as drug and alcohol addiction throughout the world."
William A. Hartman, President and CEO of Premier Biomedical, concurred saying, "We have a very talented and dedicated team to deliver breakthrough technologies."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCPINK:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our websites: http://www.premierbiomedical.com and http://www.painreliefmeds.com
About Halberd Corp.
Halberd Corp. (HALB) is a holding company and incubator for early-stage, high-growth businesses located in Southfield, Michigan. The company manufactures and sells unmanned aircrafts. Its unmanned aircrafts are intended for both private and governmental use in such diverse industries as military, oil and gas, municipal, meteorological, forestry, agriculture and coastal/border surveillance. The company's products provide platforms necessary for aerial imaging in industries and sectors as diverse as agricultural, forestry, livestock ranches, law enforcement, environmental protection agencies, coast guard, and even Hollywood.
About Gold River Production Services, Inc.: Gold River Production Services (GRPS) is dedicated to changing peoples' lives. With a unique staff of physicians, cultivators, and CBD experts, we are poised to tackle different disease states on an unprecedented level. Utilizing years of experience in herbals, rare cannabinoids, traditional and non-traditional methods of patient care, we are in the unique position to utilize CBD in the most effective ways possible. Emphasis on what already works, then augmenting effective formulas with high-quality cannabinoids in therapeutic levels to achieve unprecedented symptom control in a myriad of disease states.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
SOURCE: Premier Biomedical, Inc.
View source version on accesswire.com: